Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Intercept Pharma Shares Rise on FDA Acceptance of NDA for Liver Fibrosis Treatment

Shares of Intercept Pharmaceuticals rose today after the company reported that the U.S. Food and Drug Administration accepted its NDA for obeticholic acid (OCA) for the treatment of liver fibrosis due to NASH and granted priority review status. This morning biopharmac...
Streetwise Reports | November 27, 2019 |

Biopharma Has Three 2020 Shots on Goal in Pediatric Liver Diseases

The events in that trio are presented in a ROTH Capital Partners report. In a Feb. 3 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that Albireo Pharma Inc. (ALBO:NASDAQ) plans to launch three clinical trials this year in the same num...
Streetwise Reports | February 10, 2020 |

The Drill is Turning to Uncover the Stargate II Anomaly: A Large Gold Pipe?

Game-Changer Potential for Ximen Mining The large Stargate II Anomaly (red) at the Gold Drop Property ( see video here ). Today, Ximen Mining Corp. announced that drilling has started on the Gold Drop Property in southern British Columbia to test the Sta...
Stephan Bogner | October 2, 2019 |

FDA Grants Breakthrough Status to Biopharma's Lead Candidate for Liver Disease

The California firm's most advanced asset is advancing through Phase 2b, according to a ROTH Capital Partners report. In a Feb. 19 research note, analyst Yasmeen Rahimi reported that CymaBay Therapeutics Inc. (CBAY:NASDAQ) is having a strong Q1/19 with respect to cont...
Streetwise Reports | February 26, 2019 |

Promising Results from Shallow & Deep Drilling at Gold Drop

Full size / Photo of drill core from the Stargate II Anomaly showing pencil magnet deflected by magnetite disseminated in greenstone with epidote alteration. Shallow and deep drilling at Gold Drop produce highly promising results and findings ...
Stephan Bogner | October 24, 2019 |

Biopharma Reports Consistent 'Phase 2 Liver Fat (NASH and NAFLD) Results'

The new data are reviewed and updates are provided on Can-Fite BioPharma's other clinical studies, including one for COVID-19, in this Dawson James research report. In an April 20 research note, Dawson James analyst Jason Kolbert wrote that results from Can...
Streetwise Reports | April 23, 2020 |

NGM Biopharma Shares Rise on Positive Topline Data from Phase 2 NASH Trial

Shares of NGM Biopharmaceuticals reached a new 52-week intraday high price after the company posted positive topline data from Cohort 4 of its Phase 2 study of aldafermin in NASH Patients. On a day when world financial markets traded lower across the board, ...
Streetwise Reports | February 25, 2020 |

Shares Rise as The Medicines Company Reports Positive Topline Results...

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hype...
Streetwise Reports | September 26, 2019 |

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study

Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients. Clinical-stage biotechnology...
Streetwise Reports | July 2, 2020 |

Assembly Biosciences Stock Sizzles Following Phase 2a Announcement and Buy Rating from Mizuho

Good news is piling up for this healthcare stock engaged in the treatment of hepatitis B as it trades at 5X its average volume with a 30% stock price gain over previous close. Assembly Biosciences Inc (ASMB:NASDAQ) announced in a press release on October 16, 2019, ...
Streetwise Reports | October 17, 2019 |
1 2 3 4